Heparin plasma was thawed and measured using a custom-made ELISA against human soluble sortilin. In short, 96-well plate Nunc Maxisorp was coated with anti–human soluble sortilin [custom made against EC domain as described by Petersen et al. (32)] 1 μg per well in 55 mM NaHCO3 pH 9.8. The wells were subsequently blocked with 5% bovine serum albumin (BSA) (Sigma A7888) in phosphate-buffered saline (PBS) (pH 7.4). Washing was done in PBS-T (pH 7.4). Sample, internal control, and standard were incubated overnight at 4°C. Standard curve was made from 0.625 to 160 ng/mL of purified human soluble sortilin (21). The in-house generated detection antibody (MABN1792, Sigma) was diluted in PBS-T with 1% BSA to 1 μg/mL. One hundred microliters of the solution was added to each well and allowed to incubate at 37°C for 1 h. Finally, plates were incubated with peroxidase-conjugated goat anti–mouse immunoglobulin G (Dako) for 30 min at room temperature and rinsed five times before addition of o-phenylenediamine dihydrochloride (Dako) mixed with hydrogen peroxide. The reaction was stopped using 0.5 M sulfuric acid, and absorbance was subsequently measured at 490 nm.
To investigate if the anticoagulant used (heparin vs. EDTA) affected the measurable sortilin level, a subset of 44 Dan-NICAD individuals was randomly selected. In a paired design, sortilin was measured again in both EDTA and heparin plasma samples using the same approach as described above.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.